Cargando…
Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (M(pro) or 3CL(pro)) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replicati...
Autores principales: | Mengist, Hylemariam Mihiretie, Mekonnen, Daniel, Mohammed, Ahmed, Shi, Ronghua, Jin, Tengchuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883113/ https://www.ncbi.nlm.nih.gov/pubmed/33597888 http://dx.doi.org/10.3389/fphar.2020.630500 |
Ejemplares similares
-
Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2021) -
Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro)
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2020) -
In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from Thymus schimperi
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2023) -
Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2021) -
QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease
por: Song, Fucheng, et al.
Publicado: (2023)